Casa Systems Debuts New Axyom 5G Core
Superior network performance enables service providers to drive new revenue streams and reduce costs
ANDOVER, Mass., Feb. 26, 2018 (GLOBE NEWSWIRE) -- Casa Systems (NASDAQ:CASA), a leading provider of end-to-end network infrastructure technology solutions for wireline and wireless networks today announced it will debut its 5G core at this year's Mobile World Congress. Designed to bring new levels of flexibility to mobile networks, Casa's 5G core delivers the performance and service creation capabilities that service providers need to realize potential new revenues and operational efficiencies from mobile core transformations.
Built on Casa's AxyomTM Ultra-Broadband Cloud, Casa's 5G Core was developed for the unique demands on mobile core software functions in edge computing and data center environments where those functions need to scale in multiple dimensions, be composed into an expanded range of 5G services, and be securely exposed to other functions. The Axyom 5G Core architecture incorporates industry standards including a micro-service based architecture, as well as separation of control and user plans, but also leverages Casa's design innovations that dramatically improve performance, reduce resource requirements, and increase ease of operation.
Casa's 5G core runs on standard servers in containers or virtual machines and is optimized for a distributed, virtual compute environment to deliver superior performance and surpass industry benchmarks:
- Superior performance: Up to 5X greater throughput per vCPU when compared to competitors. This performance will help service providers in their quest for both OPEX and CAPEX cost reductions.
- Lean computing requirements: An industry leading, minimal vCPU Virtual Network Function (VNF) footprint ensures efficient resource utilization and delivers high user-plane performance including at the edge of the network.
- Simplified network evolution: Casa's Axyom 5G core efficiently controls 4G devices as well, enabling the benefits of the 5G core architecture in 4G networks.
- Differentiated Scaling: Addition of a new scaling dimension with the support for both vertical and horizontal scaling. Vertical scaling delivers the ability to dynamically increase and decrease vCPUs within a single VNF that translates to more efficient and responsive use of compute resources.
- Superior flexibility: Casa's 5G Control and User Plane Separation (CUPS) solutions provides independent scaling and the ability to locate functions in a centralized data center or at the distributed network edge for Multi-access Edge Computing (MEC) applications.
- Simplified service provisioning: Up to 6X faster ability to bring up new services that allows service providers to rapidly respond to new market opportunities.
Casa's solution supports the 5G New Radio (NR) standard and key 5G Core capabilities including network slicing, service chaining, network programmability, and secure network exposure - all of which help service providers handle growing network traffic, monetize network capabilities and achieve greater service agility.
At this week's Mobile World Congress in Barcelona, Casa Systems' will debut its Axyom 5G Core featuring demonstrations of its mobile core multi-dimensional scaling capabilities. Casa will also showcase other new solutions including a Cellular IoT Optimized Core, an Enhanced Small Cell Core, and new indoor and outdoor small cells.
"Casa has a clear vision for the future - a virtualized, converged and distributed network. We are reimagining the network infrastructure to deliver high performance and operational efficiency in the 5G era," said Jerry Guo, CEO of Casa Systems. "Our Axyom solutions deliver on key dimensions including Gbps per vCPU, and our 5G Core gives service providers the performance, flexibility, and economics they need to capitalize on growing demand and new use cases."
About Casa Systems, Inc.
Casa Systems, Inc. (NASDAQ:CASA) delivers software solutions that enable wireless and wireline broadband providers to meet the growing demand for gigabit bandwidth and services. We provide a suite of distributed and virtualized solutions for fixed and mobile 5G ultra-broadband networks. Our solutions are commercially deployed in over 70 countries serving more than 400 customers, including regional service providers as well as some of the world's largest Tier 1 broadband service providers.
To arrange a briefing or product demonstration, please contact us at email@example.com or visit our website at http://www.casa-systems.com.
Casa Systems, Inc.
100 Old River Road
Andover, Mass. 01810
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Casa Systems, Inc. via Globenewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Følg saker fra GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra GlobeNewswire
DalCor Announces Completion of Patient Enrollment in dal-GenE, the First Phase 3 Precision Medicine Cardiovascular Outcomes Trial in Coronary Heart Disease17.12.2018 09:00 | Pressemelding
LONDON and MONTREAL, Dec. 17, 2018 (GLOBE NEWSWIRE) -- DalCor today announced the completion of patient enrollment in the dal-GenE study, the first Phase 3 precision medicine cardiovascular outcomes trial in coronary heart disease. The dal-GenE study is evaluating the efficacy of the CETP inhibitor dalcetrapib to reduce clinical cardiovascular events in patients with the AA ADCY9 genotype who have had a recent acute coronary syndrome (ACS). The study has enrolled over 6,000 patients and is being conducted in 680 sites in 32 countries. “The accelerated enrollment of patients in the dal-GenE study reflects the scientific enthusiasm and commitment among the medical community to bring the right medicine to the right patient,” said Dr. Jean-Claude Tardif from the Montreal Heart Institute. “ADCY9 genetic testing to identify the appropriate patients for treatment with dalcetrapib has the potential to provide a genetically targeted therapy to improve clinical outcomes. This approach could pave
Compuware Announces Day One Support for IBM CICS Transaction Server for z/OS V5.514.12.2018 18:02 | Pressemelding
SoftServe Achieves Machine Learning Specialization in Google Cloud Partner Program14.12.2018 13:00 | Pressemelding
Google Cloud recognizes SoftServe’s technical proficiency and proven success AUSTIN, Texas, Dec. 14, 2018 (GLOBE NEWSWIRE) -- SoftServe, a leading digital authority and consulting company, announces it achieved the Machine Learning Partner Specialization in the Google Cloud Premier Partner Program. The Partner Specialization affirms SoftServe’s expertise and success building customer solutions in the machine learning field using Google Cloud Platform (GCP) technology. The Google Cloud Partner Specialization Program is designed to provide Google Cloud customers with qualified partners that demonstrate technical proficiency in the specialized solution and service areas. Specifically, the Machine Learning Specialization demonstrates SoftServe’s expertise in data exploration, preprocessing, model training, model evaluation, model deployment, online prediction, and Google Cloud’s pre-trained machine learning APIs. “We teach machines to learn, read, see and understand business data, and make
Minerals Technologies Announces Price Increases for Specialty Minerals Products in Europe14.12.2018 00:01 | Pressemelding
NEW YORK, Dec. 13, 2018 (GLOBE NEWSWIRE) -- Specialty Minerals Inc. (“SMI”), a subsidiary of Minerals Technologies Inc., announced today that effective February 1, 2019, it will increase prices by up to 10% for all coated ultrafine precipitated calcium carbonate (PCC) from SMI’s Lifford Specialty PCC facility in Birmingham, UK, subject to individual customer contracts and market provisions. The price increases reflect increased market demand for higher performance materials, as well as significant inflation in input, raw material and logistics costs. About Minerals Technologies Inc. New York-based Minerals Technologies Inc. (MTI) is a resource- and technology-based growth company that develops, produces and markets worldwide a broad range of specialty mineral, mineral-based and synthetic mineral products and related systems and services. MTI serves the paper, foundry, steel, construction, environmental, energy, polymer and consumer products industries. The Company reported sales of $1.
Synthesio to Bring Proven Ipsos Data Science to Artificial Intelligence13.12.2018 17:03 | Pressemelding
Synthesio's Next-Generation Social Media Intelligence to Raise Unseen Insights to the Surface, Faster NEW YORK, Dec. 13, 2018 (GLOBE NEWSWIRE) -- Synthesio, an Ipsos company, and also the leading Social Media Intelligence Suite, today announced the plans for its next-generation Artificial Intelligence (AI) engine. The project will combine Synthesio’s AI technology with Ipsos’ data science. The combination will power upcoming Synthesio capabilities to help users find insights faster, remove guesswork, and make informed business decisions across a variety of use cases. “Our goal has always been to provide customers with meaningful data, visualized so that they can make strategic business decisions,” explained Loic Moisand, CEO & Founder of Synthesio. “The less guesswork that a company has to make, and the less time that it takes users to find meaningful insights, the more time for data-backed business decisions. We are really pleased that we can leverage the data science capabilities dev
XBiotech Announces Publication of Post-Hoc Analysis for Phase III Colorectal Cancer Study13.12.2018 14:00 | Pressemelding
Biomarkers Predict Significantly Higher Rates of Treatment Response to Bermekimab in Advanced Cancer Patients AUSTIN, Texas, Dec. 13, 2018 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) announced today the publication of findings on key biomarker analysis of colorectal cancer patients treated with bermekimab in its European Phase III study. The manuscript, entitled, “Interleukin-1 Receptor Antagonist (IL-1ra) Levels Predict Favorable Outcome after Bermekimab, a First-in-Class True Human Interleukin-1α Antibody, in a Phase III Randomized Study of Advanced Colorectal Cancer”, has been published online in the journal OncoImmunology. The findings report that patients with relatively low levels of IL-1ra or IL-6 were more likely to respond to bermekimab therapy and achieve the study’s primary endpoint. The study’s primary endpoint measured a combination of physical symptoms—pain, fatigue, anorexia and muscle wasting—which tend to worsen with advanced cancer, to assess whether these sympto